Building on its guiding principles of insight and innovation, AI-enabled precision medicine company RowAnalytics Ltd has undertaken a comprehensive rebrand to become PrecisionLife Ltd, culminating in the launch of a new website and early-stage partnering model.
The company’s core platform, precisionlife®, is a radical new approach to complex disease analysis, stratifying patients based on their genomic, phenotypic and clinical data. The powerful platform provides unique insights into the combinatorial signatures driving complex diseases such as ALS, Alzheimer’s disease, asthma and breast cancer. precisionlife stratifies patient populations with unprecedented detail and uses this knowledge to identify and validate novel targets, biomarkers and drug discovery and repurposing candidates. The company is engaged in discovery and delivery of innovative precision medicine opportunities in multiple areas of unmet medical need.
Working with pharma and biotech, healthcare and disease charities, precisionlife operates a scalable early-stage partnering model to develop and out-license multiple novel in vitro/in vivo validated assets with comprehensive supporting biological data packages. These assets are fully annotated and pre-selected to meet known drug discovery and drug repurposing criteria. With offices in the UK, USA, Denmark and Poland, the company is well-positioned to collaborate on an international scale.
Dr Steve Gardner, precisionlife co-founder and CEO, commented: “This rebrand comes at a very exciting time for the company. As we expand our TargetBank™ portfolio of validated assets, we felt it was time to consolidate our branding and ensure our website effectively showcases our capabilities, value and impact for the life sciences and healthcare markets.”
Dr Veronique Bouchet, precisionlife CMO and recently featured as one of the “50 Movers & Shakers in BioBusiness 2019”, commented: “The decision to adopt the precisionlife brand across the company was driven by the dynamic, fast-moving nature of the AI sector and our position at the forefront of delivering precision medicine. Our new brand identity and website reflect this and I am excited about our next phase of growth.”
Notes to the Editor
Established as RowAnalytics by Dr Steve Gardner and Dr Gert L. Møller in 2013, the company was built on a shared vision to bring a new level of analytical capability to computational biology, genomic medicine and healthcare. Its proprietary precisionlife platform is built on over 30 years’ experience each in delivering new technologies and products to enable the discovery of richer and more useful links between patients, disease, targets and drugs. Today, using the precisionlife platform, thousands of targets have been screened against multiple diseases, developing a portfolio of validated assets in TargetBank™ for complex diseases with high unmet clinical need.
Dr Steve Gardner, CEO of precisionlife: email@example.com / +44 (0)1865 575170